CNK Therapeutics

CNK Therapeutics is a South Korean biotechnology company dedicated to advancing circular RNA (circRNA) technology for therapeutic applications. The company's platform focuses on the structural advantages of circRNA, such as increased stability and resistance to exonucleases, to provide longer-lasting protein expression compared to traditional linear mRNA. CNK Therapeutics is developing a diverse pipeline targeting oncology, rare diseases, and infectious disease vaccines. By optimizing RNA design and delivery, the company seeks to establish a new standard for durable and effective RNA-based medicines. Their research aims to overcome the limitations of current mRNA therapies, particularly regarding half-life and immunogenicity. The firm is currently in the pre-clinical stage, focusing on validating its platform across multiple disease models.